Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Monoclonal Antibody Staining Improves Detection of Gastric Bacteria

By LabMedica International staff writers
Posted on 30 Jan 2011
Immunohistochemical staining of endoscopic gastric biopsies with specific antibodies identifies the pathogenic bacteria Helicobacter pylori in upper gastrointestinal diseases. More...


Tissue sections cut from paraffin blocks can be immunochemically stained with polyclonal or specific monoclonal antibodies and examined microscopically to determine the presence or absence of H. pylori.

A retrospective study, conducted by PLUS Diagnostics Laboratories, Union, NJ, USA), used archived material of 300 biopsies that previously had been demonstrated as H. pylori gastritis. The polyclonal antibody immunohistochemical method (NCL-HPp) were compared with slides stained with a Novocastra monoclonal antibody, clone UCL3R (MHP). A monoclonal slide and a polyclonal slide were each prepared with two sections from the same level, that were cut at four micrometer thickness, and immunohistochemical staining was performed on the Bond instrument (Leica Microsystems, Wetzlar, Germany), from whom both the monoclonal and polyclonal antibodies are available.

All study immunohistochemical stained tissue slides were reviewed microscopically by two gastrointestinal pathologists from PLUS Diagnostics with extensive experience in interpretation of immunohistochemical stains and H. pylori assessment. Each set of histological sections were scored, and the results recorded. Results were classified as either positive or negative for H. pylori. The definition of a positive result was the presence of any stained organisms resembling H. pylori bacteria. The definition of negative was the absence of any stained H. pylori-like bacteria.

The sensitivity of the two methods was comparable with 96.2% of the cases identified by the monoclonal antibody method and 98.5% identified by the polyclonal antibody method. The pathologists' evaluations showed that 75.6% of cases displayed high quality organism morphology with the MHP compared with only 34.4% using NCL-HPp, and that 95.8% of cases displayed high quality background staining MHP compared with 87.3% using NCL-HPp.

The authors concluded that the new H. pylori monoclonal ULC3R antibody reagent (MHP) when compared to the polyclonal antibody, NCL-HPp, shows improved quality of organism morphology clarity and reduced nonspecific background staining, whereas the sensitivity of the two methods was comparable. The study was published in January 2011, in LabMedicine.

Related Links:
Leica Microsystems
PLUS Diagnostics




Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
Gold Member
Hematology Analyzer
Medonic M32B
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.